Entry Detail
| General information | |
| Database: | DB00951 |
| Objective: | Pazopanib, an inhibitor of kinases including vascular endothelial growth factor receptor, demonstrated impressive activity in progressive metastatic differentiated thyroid cancer, prompting its evaluation in anaplastic thyroid cancer (ATC). |
| Authors: | Bible KC, et al |
| Title: | A multiinstitutionalphase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer. |
| Journal: | J Clin Endocrinol Metab. |
| Year: | 2012 |
| PMID: | 22774206 |
| Trial Design | |
| Clinical Trial Id: | NCT01236549 |
| Agent: | pazopanib |
| Target: | Plateletderived growth factor receptor Mast/stem cell growth factor receptor Vascular endothelial growth factor receptor 2 |
| Cancer Type: | thyroid cancer |
| Cancer Subtype: | advanced anaplastic thyroid cancer |
| Therapy Type: | mono |
| Therapeutic Combination Type: | NA |
| Therapeutic Combination Content: | NA |
| Study Type: | A multiinstitutionalphase II trial |
| Key Patients Feature: | patients 18 yr of age or older with histologically confirmed advanced/metastatic anaplastic thyroid cancer (central pathology review was not required). |
| Biomarker: | NA |
| Biomark Analysis: | NA |
| Control Group Info: | single arm |
| Treatment Info: | continuously administered 800 mg pazopanib daily by mouth (designed to provide 90% chance of detecting a response rate of >20% at the 0.10 significance level when the true response rate is >5%), were undertaken. |
| Primary End Point: | Response Evaluation Criteria in Solid Tumors (RECIST) response. |
| Secondary End Point: | NA |
| Patients Number: | 33 |
| Trial Results | |
| DLT_MTD: | NA |
| Objective Response Rate: | NA |
| Disease Control Rate: | NA |
| Median Time to Progression: | 62 d |
| Median PFS A vs. C: | NA |
| Median OS A vs. C: | 111 d |
| Adverse Event(agent arm): | The most common severe toxicities (National Cancer Institute Common Toxicity CriteriaAdverse Events version 3.0 grade 3 or greater possibly, probably or definitely related to treatment) were hypertension (13%) and pharyngolaryngeal pain (13%). |
| Conclusions: | Despite preclinical in vivo activity in ATC, pazopanib has minimal singleagent clinical activity in advanced ATC |